Peter G. Neiman, Seth B. Orkand and Peter K. Vigeland of WilmerHale write that although the Second Circuit's recent decision in 'Caronia' addressed a prosecution based only on truthful speech by a pharmaceutical sales representative, the logic of the decision would seem to reach more broadly, calling into question the government's theory underlying many prior off-label promotion cases which had resulted in large criminal fines, forfeitures, and related civil settlements.
Revisiting 'Off-Label' Drug Promotion Resolutions in Light of 'Caronia'
New York Law Journal
February 28, 2013
This article requires premium access
This article requires premium access to The New York Law Journal. Please sign in or subscribe to read the full text.